Why SPDR Biotech ETF (XBI) fell 2.03%
SPDR Biotech ETF (XBI) fell 2.03% on November 17, 2026 — FDA rejection of a closely watched cancer drug hits biotech.
What happened
The FDA declined to approve one of biotech's most closely watched cancer drugs, a rejection the FT says is a blow to China's biotech industry because the drug was developed there.
Why it moved
A high-profile rejection forces the market to lower its approval odds for similar late-stage assets, which compresses multiples across a basket of small and mid-cap biotechs.
Why it matters
This sits inside a Healthcare & Biotech theme where GLP-1 obesity adoption and a small-cap biotech bid had lifted Lilly and Hims.
What would break the thesis
If the company secures a clear path to approval through new data or a quick resubmission, the read-through fades and the group can recover.